Patients with Growth-Related Disorders and Caregivers Prefer the Somapacitan Device to the Somatrogon Device: Results from a Randomized Crossover Study Assessing Device Preference and Ease of Use Following Simulated Injections
The somapacitan device was preferred to the somatrogon device by a majority of participants. More participants considered the somapacitan device to be easy or very easy to use than the somatrogon device.
Authors
- Niklas Kahr Rasmussen
- Claus Sværke (ORCID: https://orcid.org/0009-0003-8149-841X)
- Johan Medina (ORCID: https://orcid.org/0000-0002-4454-3539)
- Emily A. Hildebrand
- Gitte Ter-Borch
- Nicky Kelepouris (ORCID: https://orcid.org/0000-0003-2445-2338)
- Jesper Skov Neergaard (ORCID: https://orcid.org/0000-0002-3034-8038)
- Maya Gonczi
- Shahid Akhtar (ORCID: https://orcid.org/0000-0003-0326-5445)
- Birgitte Berg
- Sophie Hamilton
Institutions
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk (United States) (US)
- Human Factors (Norway) (NO)
Publication Details
- Journal
- Medical Devices Evidence and Research
- Published
- 2024-10-01
- DOI
- https://doi.org/10.2147/mder.s484354
- Primary Topic
- Obesity, Physical Activity, Diet
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pediatric Endocrine Society
- Novo Nordisk